NanoVibronix UroShield Study Published; Shows 86% UTI Reduction, 70% Fewer Blockages, Promotes Adoption For Patients With Indwelling Urinary Catheters

UroShield Cited as Effective in Preventing CAUTIs and Blockages, Having a Major Impact on Quality of Life and Reducing Healthcare Resource Costs

NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical technology company specializing in non-invasive therapeutic devices, today announced that an independent health service study of its UroShield® is published in The Australian and New Zealand Continence Journal.

The study highlights UroShield's effectiveness in preventing catheter-associated urinary tract infections (CAUTIs) and recommends its adoption for appropriate patients with indwelling urinary catheters (IUCs). Researchers found that patients using UroShield experienced an 86% reduction in UTI incidence; 70% reduction in catheter blockages; 82.8% less bladder irrigations performed and 52.3% less catheter changes. The clinicians reported improved overall catheter comfort and a reduction in the need for catheter-related interventions.

Brian Murphy, CEO of NanoVibronix, Inc., commented, "This study underscores the benefits of UroShield in enhancing patient care by reducing CAUTI incidence and catheter blockages, minimizing catheter complications and improving overall comfort. Notably, researchers found that UroShield required less nursing time, which eased workload demands and resulted in measurable cost savings for the healthcare provider."